Search Results - "McColgan, Bryan"

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease by Loomba, Rohit, Kayali, Zeid, Noureddin, Mazen, Ruane, Peter, Lawitz, Eric J., Bennett, Michael, Wang, Lulu, Harting, Eliza, Tarrant, Jacqueline M., McColgan, Bryan J., Chung, Chuhan, Ray, Adrian S., Subramanian, G. Mani, Myers, Robert P., Middleton, Michael S., Lai, Michelle, Charlton, Michael, Harrison, Stephen A.

“…De novo lipogenesis is increased in livers of patients with nonalcoholic steatohepatitis (NASH). Acetyl-coenzyme carboxylase catalyzes the rate-limiting step…”
Get full text

Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis by Harrison, Stephen A., Abdelmalek, Manal F., Caldwell, Stephen, Shiffman, Mitchell L., Diehl, Anna Mae, Ghalib, Reem, Lawitz, Eric J., Rockey, Don C., Schall, Raul Aguilar, Jia, Catherine, McColgan, Bryan J., McHutchison, John G., Subramanian, G. Mani, Myers, Robert P., Younossi, Zobair, Ratziu, Vlad, Muir, Andrew J., Afdhal, Nezam H., Goodman, Zachary, Bosch, Jaime, Sanyal, Arun J.

“…Lysyl oxidase-like 2 contributes to fibrogenesis by catalyzing cross-linkage of collagen. We evaluated the safety and efficacy of simtuzumab, a monoclonal…”
Get full text

The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials by Sanyal, Arun J., Harrison, Stephen A., Ratziu, Vlad, Abdelmalek, Manal F., Diehl, Anna Mae, Caldwell, Stephen, Shiffman, Mitchell L., Aguilar Schall, Raul, Jia, Catherine, McColgan, Bryan, Djedjos, C. Stephen, McHutchison, John G., Subramanian, G. Mani, Myers, Robert P., Younossi, Zobair, Muir, Andrew J., Afdhal, Nezam H., Bosch, Jaime, Goodman, Zachary

“…Progression of nonalcoholic steatohepatitis (NASH) is incompletely characterized. We analyzed data on longitudinal changes in liver histology, hepatic venous…”
Get full text

Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients With Nonalcoholic Steatohepatitis by Lawitz, Eric J., Coste, Angie, Poordad, Fred, Alkhouri, Naim, Loo, Nicole, McColgan, Bryan J., Tarrant, Jacqueline M., Nguyen, Tuan, Han, Ling, Chung, Chuhan, Ray, Adrian S., McHutchison, John G., Subramanian, G. Mani, Myers, Robert P., Middleton, Michael S., Sirlin, Claude, Loomba, Rohit, Nyangau, Edna, Fitch, Mark, Li, Kelvin, Hellerstein, Marc

“…Increased de novo lipogenesis (DNL) contributes to the pathogenesis of nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase catalyzes the rate-limiting…”
Get full text

Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease by Muir, Andrew J., Levy, Cynthia, Janssen, Harry L.A., Montano‐Loza, Aldo J., Shiffman, Mitchell L., Caldwell, Stephen, Luketic, Velimir, Ding, Dora, Jia, Catherine, McColgan, Bryan J., McHutchison, John G., Mani Subramanian, G., Myers, Robert P., Manns, Michael, Chapman, Roger, Afdhal, Nezam H., Goodman, Zachary, Eksteen, Bertus, Bowlus, Christopher L.

“…Lysyl oxidase like‐2 (LOXL2) plays a central role in fibrogenesis and is elevated in the serum and liver of patients with primary sclerosing cholangitis (PSC)…”
Get full text

The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options by Younossi, Zobair, Stepanova, Maria, Sanyal, Arun J., Harrison, Stephen A., Ratziu, Vlad, Abdelmalek, Manal F., Diehl, Anna Mae, Caldwell, Stephen, Shiffman, Mitchell L., Schall, Raul Aguilar, McColgan, Bryan, Subramanian, G. Mani, Myers, Robert P., Muir, Andrew, Afdhal, Nezam H., Bosch, Jaime, Goodman, Zachary

“…[Display omitted] •Patients with cryptogenic cirrhosis or NASH cirrhosis had similar clinical and demographic profile.•Cryptogenic cirrhosis was associated…”
Get full text

1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH) by SANYAL, ARUN J., ABDELMALEK, MANAL F., CALDWELL, STEPHEN, SHIFFMAN, MITCHELL L., GHALIB, REEM, LAWITZ, ERIC, JIANG, DEYUAN, AGUILAR SCHALL, RAUL E., MCCOLGAN, BRYAN J., MYERS, ROB, DJEDJOS, STEPHEN, MUIR, ANDREW, RATZIU, VLAD, AFDHAL, NEZAM, GOODMAN, ZACHARY, BOSCH, JAIME, HARRISON, STEPHEN A.

“…Background: Diabetes is a risk factor for advanced fibrosis due to NASH, but the effect of diabetes on disease progression is not well-characterized. Here, we…”
Get full text

Effect of nicotine mouth spray on urges to vape: A randomized, placebo-controlled, pharmacodynamic clinical trial in exclusive e-cigarette users by Danielsson, Tobias, Bennet, Hedvig, McColgan, Bryan, Wang, Jianfeng

“…To determine whether nicotine mouth spray provides rapid and prolonged relief of urges to vape and measure the steady-state plasma nicotine levels during…”
Get full text

Tu1565 – Clinical Utility and Application of Noninvasive Tests of Fibrosis in the Selection of Patients with Advanced Fibrosis Due to Nash in the Phase 2 Atlas Trial by Loomba, Rohit, Alkhouri, Naim, Strasser, Simone, Wong, Vincent, Aguilar, Raul, McColgan, Bryan J., Subramanian, Mani, Djedjos, Constantine S., Myers, Robert P., Goodman, Zachary, Sheikh, Aasim, Neff, Guy, Bhandari, Bal, Gunn, Nadege, Kowdley, Kris V.

Get full text

SAT-315-Clinical utility and application of non-invasive tests of fibrosis in the selection of patients with advanced fibrosis due to NASH in the Phase 2 ATLAS trial by Loomba, Rohit, Alkhouri, Naim, Strasser, Simone, Wong, Vincent Wai-Sun, Schall, Raul Aguilar, Mccolgan, Bryan, Subramanian, Mani, Djedjos, Stephen, Myers, Robert, Goodman, Zachary, Sheikh, Aasim, Neff, Guy, Bhandari, Bal, Gunn, Nadege, Kowdley, Kris V.

Get full text

SAT-283-Plasma acylcarnitines are biomarkers of magnetic resonance imaging-proton density fat fraction response in NASH patients treated with the ACC inhibitor GS-0976 by Charlton, Michael, Lai, Michelle, Noureddin, Mazen, Tarrant, Jacqueline M., Hu, Tao, Chen, Guang, Mccolgan, Bryan, Chung, Chuhan, Chuang, Jay, Patterson, Scott D., Myers, Robert, Mantry, Parvez, Ruane, Peter, Loomba, Rohit

Get full text

SAT-352-A combination of the ACC inhibitor GS-0976 and the nonsteroidal FXR agonist GS-9674 improves hepatic steatosis, biochemistry, and stiffness in patients with non-alcoholic steatohepatitis by Lawitz, Eric, Gane, Edward, Ruane, Peter, Herring, Robert, Younes, Ziad H., Kwo, Paul, Zhang, Jie, Jia, Catherine, Chuang, Jay, Mccolgan, Bryan, Chung, Chuhan, Subramanian, Mani, Myers, Robert, Middleton, Michael, Li, Kelvin, Hellerstein, Marc, Noureddin, Mazen, Harrison, Stephen, Loomba, Rohit

Get full text

501 - Prospective Validation of the Enhanced Liver Fibrosis (ELF) Test for the Prediction of Disease Progression in a Randomized Trial of Patients with Primary Sclerosing Cholangitis (PSC) by Bowlus, Christopher L., Patel, Keyur, Hirschfield, Gideon, Guha, Neil, Chapman, Roger W., Chazouillères, Olivier, Ding, Dora, Jia, Catherine, McColgan, Bryan J, Natha, Macky, Myers, Robert P., Subramanian, Mani, McHutchison, John, Muir, Andrew J., Goodman, Zachary, Rosenberg, William, Levy, Cynthia

Get full text

Su1522 - Proof of Concept Study of an Apoptosis-Signal Regulating Kinase (ASK-1) Inhibitor (Selonsertib) in Combination with an Acetyl-Coa Carboxylase Inhibitor (GS-0976) or a Farnesoid X Receptor (FXR) Agonist (GS-9674) in NASH by Lawitz, Eric, Herring, Robert, Younes, Ziad H., Gane, Edward, Ruane, Peter J., Aguilar, Raul, Jia, Catherine, Xu, Ren, McColgan, Bryan J., Natha, Macky, Djedjos, C. Stephen, Subramanian, Mani, McHutchison, John, Myers, Robert P., Middleton, Michael S., Li, Kelvin, Hellerstein, Marc, Kwo, Paul Yien, Noureddin, Mazen, Harrison, Stephen A.

Get full text

Su1541 - Responsiveness of Controlled Attenuation Parameter (CAP) and Its Correlation with Magnetic Resonance Imagingproton Density Fat Fraction (MRI-PDFF) in a Multi-Center Clinical Trial of Subjects with Nonacoholic Steatohepatitis (NASH) by Noureddin, Mazen, Kayali, Zeid, Harrison, Stephen A., Ruane, Peter J., Gitlin, Norman, Lawitz, Eric, Bennett, Michael, Vuppalanchi, Raj, Freilich, Bradley, Harting, Eliza, McColgan, Bryan J, Natha, Macky, Myers, Robert P., Middleton, Michael S., Sirlin, Claude B., Charlton, Michael, Lai, Michelle, Mantry, Parvez S., Loomba, Rohit

Get full text

Su1521 - Preliminary Efficacy and Safety of Acetyl-Coa Carboxylase (ACC) Inhibitor GS-0976 in Patents with Compensated Cirrhosis due to NASH by Harrison, Stephen A., Noureddin, Mazen, Herring, Robert, Ruane, Peter J., McColgan, Bryan J, Natha, Macky, Kirby, Brian, Nelson, Cara, Aguilar, Raul, Jia, Catherine, Subramanian, Mani, Myers, Robert P., Middleton, Michael S., Sirlin, Claude B., Fitch, Mark, Li, Kelvin, Hellerstein, Marc, Lawitz, Eric

Get full text

Prospective Validation of the Enhanced Liver Fibrosis (ELF) Test for the Prediction of Disease Progression in a Randomized Trial of Patients with Primary Sclerosing Cholangitis (PSC) by Bowlus, Christopher L, Patel, Keyur, Hirschfield, Gideon, Guha, Neil, Chapman, Roger W, Chazouillères, Olivier, Ding, Dora, Jia, Catherine, McColgan, Bryan J, Natha, Macky, Myers, Robert P, Subramanian, Mani, McHutchison, John, Muir, Andrew J, Goodman, Zachary, Rosenberg, William, Levy, Cynthia

Get full text

354 - Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis by Sanyal, Arun, Harrison, Stephen A., Ratziu, Vlad, Abdelmalek, Manal F., Diehl, Anna Mae, Caldwell, Stephen H., Shiffman, Mitchell L., Aguilar, Raul, Jia, Catherine, McColgan, Bryan J, Natha, Macky, Myers, Robert P., Subramanian, Mani, McHutchison, John, Muir, Andrew J., Afdhal, Nezam H., Bosch, Jaime, Goodman, Zachary

Get full text

Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis by Sanyal, Arun, Harrison, Stephen A, Ratziu, Vlad, Abdelmalek, Manal F, Diehl, Anna Mae, Caldwell, Stephen H, Shiffman, Mitchell L, Aguilar, Raul, Jia, Catherine, McColgan, Bryan J, Natha, Macky, Myers, Robert P, Subramanian, Mani, McHutchison, John, Muir, Andrew J, Afdhal, Nezam H, Bosch, Jaime, Goodman, Zachary

Get full text

Unusual five amino acid insert within subtype C HIV-1 envelope contributes to dual-tropism (X4R5) by JOHNSTON WHITE, Elizabeth, MCCOLGAN, Bryan, KASSAYE, Seble, ZIJENAH, Lynn, KATZENSTEIN, David

“…During the course of HIV infection, some HIV-1 viruses switch from using the CCR5 (R5) coreceptor to using CXCR4 (X4). Here, we describe two subtype C isolates…”
Get full text